Page last updated: 2024-10-18

dalteparin and Syndrome

dalteparin has been researched along with Syndrome in 75 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
"We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment."9.13Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008)
"The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome."9.12Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007)
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin."9.12Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006)
"Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers."9.12Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006)
"A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)."9.12Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007)
"In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)."9.11A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004)
"Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared."9.11[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005)
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial."9.09Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001)
"Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0."9.09Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999)
"This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h."9.09Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."6.70Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
" Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied."5.33Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006)
"We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment."5.13Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008)
"Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin."5.12Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006)
"The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)."5.12A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006)
"Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers."5.12Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006)
"A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)."5.12Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007)
"The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome."5.12Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007)
"To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)."5.11[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004)
"In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)."5.11A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004)
"Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared."5.11[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005)
"The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial."5.09Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001)
"Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0."5.09Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999)
"This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h."5.09Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999)
"The FRISC II study addressed two key questions in the management of acute coronary syndromes: is it beneficial to extend low-molecular-weight heparin (LMWH) therapy with dalteparin beyond the initial period of acute treatment; and, is a strategy of early invasive therapy, including angioplasty and surgical revascularization, preferable to a more conservative strategy? The study focused on patients with unstable coronary artery disease (UCAD), that is, angina and non-ST-segment-elevation myocardial infarction (MI)."5.09Improving outcomes in acute coronary syndromes--the FRISC II trial. ( Kontny, F, 2001)
"On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes."4.81Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002)
" In early trials, such as FRISC (Fragmin during instability in coronary artery disease) and FRIC (Fragmin in unstable coronary artery disease), the results of extended treatment were inconclusive; however, the trial populations included patients of relatively low risk and used a once-daily dosing regimen."3.79Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. ( Husted, S; Kher, A, 2000)
"The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin."3.71Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002)
" dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH."2.70Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002)
"Lemierre's syndrome is a potentially fatal disease that usually presents with oropharyngeal infection, followed by sepsis, thrombosis of the internal jugular vein and septic emboli."2.45Unusual presentation of Lemierre's syndrome: two cases and a review. ( Brandjes, DP; Gerdes, VE; Soesan, M; van Gorp, EC; van Wissen, M, 2009)
"Lemierre's syndrome is characterized by acute oropharyngeal infection complicated by internal jugular venous thrombosis secondary to septic thrombophlebitis, and metastatic abscesses."2.43Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy. ( Jones, C; O'Reilly, BJ; Seymour, FK; Siva, TM, 2006)
" They are more predictable in action, do not require frequent activated partial thromboplastin time (aPTT) measurements and dosage adjustments, are easier to administer, and are potentially more efficacious."2.41Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. ( Monrad, ES, 2000)
"Currently, prospective clinical trials investigate the efficacy of combined use of LMWH with thrombolytics, GPIIb/IIIa blockers and the optimal dosage of LMWH during coronary interventions."2.41[Low molecular weight heparins in acute coronary syndrome]. ( Huber, K; Niessner, A; Niessner, H, 2001)
"We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel."1.35Air travel and pulmonary embolism: "economy class syndrome". ( Arora, P; Bhatia, V; Kaul, U; Mittal, A; Pandey, AK; Parida, AK, 2009)
" Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied."1.33Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006)
"Unfractionated heparin (UFH) has been considered the standard anticoagulant for patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS), yet it has limitations, including an unpredictable dose-response and intravenous administration."1.33Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. ( Goodman, S, 2005)
"To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin."1.32Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004)

Research

Studies (75)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (12.00)18.2507
2000's64 (85.33)29.6817
2010's2 (2.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
van Wissen, M1
Gerdes, VE1
van Gorp, EC1
Brandjes, DP1
Soesan, M1
Poponina, TM1
Kapilevich, NA1
Kisteneva, IV1
Markov, VA1
Novitskiĭ, VV1
Kaul, S1
Shah, PK1
Goldmann, BU1
Hamm, CW1
Huber, K1
Niessner, A1
Niessner, H1
Briassoulis, G1
Fitrolaki, MD1
Spanaki, AM1
Gill-Schuster, D1
Bergold, M1
Holzer, L1
Mooney, T1
Joseph, P1
Bhatia, V1
Arora, P1
Parida, AK1
Mittal, A1
Pandey, AK1
Kaul, U1
Jones, HU1
Muhlestein, JB1
Jones, KW1
Bair, TL1
Lavasani, F1
Sohrevardi, M1
Horne, BD1
Doty, D1
Lappe, DL1
Gratsianskiĭ, NA3
Levine, GN1
Ferguson, JJ5
Antman, EM5
Bates, ER2
Cohen, M6
Every, NR1
Harrington, RA2
Pepine, CJ1
Theroux, P3
Averkov, OV2
Slavina, NN2
Dobrovol'skiĭ, AB1
Grines, CL1
O'Neill, W1
Lee, DS1
Bhatt, DL1
Moliterno, DJ1
Peacock, WF1
Ellis, SG1
Topol, EJ2
Hermiller, JB1
Macie, C1
Forbes, L1
Foster, GA1
Douketis, JD1
Simoons, ML2
Bobbink, IW1
Boland, J1
Gardien, M1
Klootwijk, P1
Lensing, AW1
Ruzyllo, W1
Umans, VA1
Vahanian, A1
Van De Werf, F1
Zeymer, U1
Steg, PG2
Juliard, JM1
Galla, JM1
Mahaffey, KW4
Rokos, IC1
Goodman, S1
Califf, RM2
Petersen, JL2
Hasselblad, V1
Katsouras, C1
Michalis, LK1
Papamichael, N1
Adamides, K1
Naka, KK1
Nikas, D1
Goudevenos, JA1
Sideris, DA1
Buckmaster, ND1
Heazlewood, V1
Scott, IA1
Jones, M1
Haerer, W1
Hillier, K1
Fitchett, DH1
Langer, A3
Armstrong, PW2
Tan, M3
Mendelsohn, A2
Goodman, SG4
Bozovich, GE2
Dos Santos, A1
Gurfinkel, EP2
Gibson, CM1
Morrow, DA1
Murphy, SA2
Palabrica, TM1
Jennings, LK1
Stone, PH1
Lui, HH1
Bulle, T1
Lakkis, N1
Kovach, R1
Cohen, DJ1
Fish, P1
McCabe, CH3
Braunwald, E2
Waksman, R1
Wolfram, RM1
Torguson, RL1
Okubagzi, P1
Xue, Z1
Suddath, WO1
Satler, LF1
Kent, KM1
White, HD2
Kleiman, NS1
Lokhnygina, Y1
Pieper, KS1
Chiswell, K1
Chew, DP1
Berdan, LG1
Aylward, PE1
Nessel, CC1
Jolly, S1
Fitchett, D1
Kukla, P1
Bryniarski, L1
Korpak-Wysocka, R1
Bartuś, S1
Giszterowicz, D1
Dobrowolski, W1
Dudek, D1
Oliveira, GB1
Avezum, A1
Anderson, FA1
Budaj, A2
Dabbous, OH1
Goldberg, RJ1
Brieger, D2
Fox, KA3
Gore, JM1
Granger, CB3
Cardoso, R1
Gonçalo, M1
Tellechea, O1
Maia, R1
Borges, C1
Silva, JA1
Figueiredo, A1
Fazel, R1
Froehlich, JB1
Williams, DM1
Saint, S1
Nallamothu, BK1
Bassand, JP2
Mehta, SR2
Wallentin, L8
Piegas, LS1
Valentin, V1
Moccetti, T1
Chrolavicius, S2
Afzal, R2
Yusuf, S3
Friedewald, VE1
Roberts, WC1
Little, M1
Johnstone, C1
Eikelboom, JW1
Faxon, DP1
Peters, RJ1
Watters, M1
James, JK1
Sacks, DB1
Rifai, N1
Cannon, CP1
Gurfinkel, E1
Duronto, E1
Colorio, C1
Bozovich, G1
Mautner, B2
Purcell, H1
Fox, KM1
Weber, S1
Laramée, P1
Huynh, T1
Borzak, S1
Diodati, JG1
Squire, IB1
Deckelbaum, LI1
Thornton, AR1
Harris, KE1
Sax, FL1
Lo, MW1
Monrad, ES1
Galli, M1
Santopinto, J1
Torres, V1
Marcos, E1
Pechlaner, C1
Gritsch, W1
Wiedermann, C1
Vila, V1
Martínez-Sales, V1
Réganon, E1
Peris, E1
Perez, F1
Ruano, M1
Aznar, J1
Solanki, V1
Gaynor, M1
Booth, V1
MacDonald, R1
Freedman, SB1
Massel, D1
Cruickshank, MK1
Becker, RC1
Spencer, FA1
Gibson, M1
Rush, JE1
Sanderink, G1
Ball, SP1
James, S1
Armstrong, P1
Califf, R1
Husted, S2
Kontny, F2
Niemminen, M1
Pfisterer, M1
Casserly, IP1
Lindahl, B3
Lindbäck, J1
Jernberg, T1
Johnston, N2
Stridsberg, M1
Venge, P2
Mälarstig, A1
Siegbahn, A3
Menger, MD1
Rupec, RA1
Boneberger, S1
Ruzicka, T1
Oldgren, J1
Frostfeldt, G1
Ahlberg, G1
Gustafsson, G1
Helmius, G1
Nygren, A1
Swahn, E1
Arnheim, K1
Holmes, DR1
Kher, A1
Megalopoulos, A1
Vasiliadis, K1
Tsachalis, T1
Tsalis, K1
Blouhos, K1
Alexandridou, S1
Betsis, D1
Jones, C1
Siva, TM1
Seymour, FK1
O'Reilly, BJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667]43 participants (Actual)Interventional2004-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

13 reviews available for dalteparin and Syndrome

ArticleYear
Unusual presentation of Lemierre's syndrome: two cases and a review.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:6

    Topics: Acenocoumarol; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Deglutition Disorders; Diarrhea; F

2009
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:7

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; H

2000
[Low molecular weight heparins in acute coronary syndrome].
    Herz, 2001, Volume: 26 Suppl 1

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; En

2001
Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 60, Issue:2

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary Disease; Enoxapari

2003
The role of enoxaparin in interventional management of patients with acute coronary syndromes.
    Journal of interventional cardiology, 2003, Volume: 16, Issue:5

    Topics: Acute Disease; Anticoagulants; Blood Coagulation Factors; Cardiac Catheterization; Combined Modality

2003
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Myoc

2005
Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
    The American journal of cardiology, 2000, Apr-27, Volume: 85, Issue:8A

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin, Low-Molecular

2000
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
    American heart journal, 2002, Volume: 143, Issue:5

    Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th

2002
[Adverse cutaneous drug reactions].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:50

    Topics: Acneiform Eruptions; Dalteparin; Diagnosis, Differential; Drug Eruptions; Eosinophilia; ErbB Recepto

2007
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
    Der Internist, 2000, Volume: 41, Issue:1

    Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca

2000
Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes.
    Scandinavian cardiovascular journal : SCJ, 2000, Volume: 34, Issue:1

    Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Injections, Intraven

2000
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Annals of medicine, 2000, Volume: 32 Suppl 1

    Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial

2000
Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy.
    The Journal of laryngology and otology, 2006, Volume: 120, Issue:6

    Topics: Abducens Nerve Diseases; Adolescent; Anti-Bacterial Agents; Cefotaxime; Female; Follow-Up Studies; H

2006

Trials

29 trials available for dalteparin and Syndrome

ArticleYear
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:8

    Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female;

2004
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischa
    European heart journal, 1999, Volume: 20, Issue:21

    Topics: Adult; Angina, Unstable; Anticoagulants; Double-Blind Method; Female; Humans; Male; Myocardial Infar

1999
[Enoxaparin failed to show superiority to unfractionated heparin in patients with non ST-elevation acute coronary syndrome in a phase of A to Z trial].
    Kardiologiia, 2003, Volume: 43, Issue:6

    Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome; Treatment Fa

2003
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;

2003
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    The Journal of invasive cardiology, 2004, Volume: 16, Issue:2

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi

2004
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
    Journal of the American College of Cardiology, 2004, Jun-16, Volume: 43, Issue:12

    Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angiotensin-Conve

2004
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Acute Disease; Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; H

2005
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
    Kardiologiia, 2005, Volume: 45, Issue:12

    Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag

2005
Using a clinical pathway and education to reduce inappropriate prescribing of enoxaparin in patients with acute coronary syndromes: a controlled study.
    Internal medicine journal, 2006, Volume: 36, Issue:1

    Topics: Angina, Unstable; Anticoagulants; Critical Pathways; Drug Utilization; Enoxaparin; Female; Hospitals

2006
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
    American heart journal, 2006, Volume: 151, Issue:2

    Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male;

2006
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Journal of the American College of Cardiology, 2006, Jun-20, Volume: 47, Issue:12

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin

2006
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:8

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F

2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    American heart journal, 2006, Volume: 152, Issue:6

    Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Transfusion; Coronary Dis

2006
Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
    The American journal of cardiology, 2007, Jan-15, Volume: 99, Issue:2

    Topics: Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Female; Follow-Up Studies; Heparin; Hum

2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Annals of internal medicine, 2007, Sep-04, Volume: 147, Issue:5

    Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac;

2007
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Journal of the American College of Cardiology, 2007, Oct-30, Volume: 50, Issue:18

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cohort Studies; Double-Blind Metho

2007
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
    Journal of the American College of Cardiology, 1998, Volume: 31, Issue:2

    Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow-

1998
Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
    Journal of thrombosis and thrombolysis, 1999, Volume: 8, Issue:3

    Topics: Biomarkers; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Female; Fibrinol

1999
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    International journal of cardiology, 1999, Dec-01, Volume: 71, Issue:3

    Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardi

1999
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    American heart journal, 2001, Volume: 141, Issue:4

    Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans;

2001
Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Haematologica, 2001, Volume: 86, Issue:7

    Topics: Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Hemostatics; Heparin;

2001
The SYNERGY trial: study design and rationale.
    American heart journal, 2002, Volume: 143, Issue:6

    Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Fibrinol

2002
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
    European heart journal, 2002, Volume: 23, Issue:19

    Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis

2002
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
    Journal of the American College of Cardiology, 2005, Feb-15, Volume: 45, Issue:4

    Topics: Acute Disease; Aged; Angina, Unstable; Dalteparin; Electrocardiography; Female; Fibrinolytic Agents;

2005
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:7

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers; CD40 Ligand; Coronary Dise

2006
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    American heart journal, 2008, Volume: 155, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug

2008
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
    Journal of the American College of Cardiology, 1999, Volume: 33, Issue:3

    Topics: Adult; Aged; Biomarkers; Chemotherapy, Adjuvant; Coronary Angiography; Coronary Circulation; Daltepa

1999
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Annals of medicine, 2000, Volume: 32 Suppl 1

    Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial

2000
Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Clinical cardiology, 2001, Volume: 24, Issue:3 Suppl

    Topics: Adult; Angina, Unstable; Anticoagulants; Dalteparin; Female; Humans; Male; Myocardial Infarction; My

2001

Other Studies

34 other studies available for dalteparin and Syndrome

ArticleYear
[Risk stratification in acute coronary syndrome].
    Herz, 2001, Volume: 26 Suppl 1

    Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clin

2001
Cerebral venous thrombosis associated with seat belt syndrome.
    The Journal of trauma, 2009, Volume: 67, Issue:6

    Topics: Accidents, Traffic; Child; Diagnosis, Differential; Heparin, Low-Molecular-Weight; Humans; Intracran

2009
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2018, Volume: 53, Issue:5

    Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ

2018
Purple toes syndrome following stroke thrombolysis and warfarin therapy.
    Internal medicine journal, 2014, Volume: 44, Issue:1

    Topics: Acute Kidney Injury; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism, Cholesterol;

2014
Air travel and pulmonary embolism: "economy class syndrome".
    The Journal of the Association of Physicians of India, 2009, Volume: 57

    Topics: Adult; Aircraft; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Fac

2009
Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports.
    Circulation, 2002, Sep-24, Volume: 106, Issue:12 Suppl 1

    Topics: Acute Disease; Aged; Angina, Unstable; Blood Component Transfusion; Coronary Artery Bypass; Coronary

2002
[Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
    Kardiologiia, 2003, Volume: 43, Issue:9

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Fibrinolytic Ag

2003
Role of enoxaparin in the invasive management of the ACS patient.
    The Journal of invasive cardiology, 2004, Volume: 16, Issue:2

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi

2004
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
    Chest, 2004, Volume: 125, Issue:5

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E

2004
Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit.
    European heart journal, 2004, Volume: 25, Issue:19

    Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome

2004
Enoxaparin versus heparin: the SYNERGY trial from an emergency medicine perspective.
    Drugs, 2005, Volume: 65, Issue:10

    Topics: Acute Disease; Anticoagulants; Coronary Disease; Emergency Medicine; Enoxaparin; Heparin; Humans; Ra

2005
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    American heart journal, 2005, Volume: 149, Issue:4 Suppl

    Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum

2005
Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
    American heart journal, 2005, Volume: 149, Issue:4 Suppl

    Topics: Acute Disease; Anticoagulants; Arrhythmias, Cardiac; Enoxaparin; Eptifibatide; Heparin; Humans; Myoc

2005
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    American heart journal, 2005, Volume: 149, Issue:4 Suppl

    Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl

2005
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    American heart journal, 2006, Volume: 151, Issue:4

    Topics: Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Mal

2006
[Transient left ventricular apical ballooning syndrome--a case report].
    Kardiologia polska, 2007, Volume: 65, Issue:2

    Topics: Aged; Amlodipine; Echocardiography, Doppler; Electrocardiography; Enoxaparin; Female; Humans; Simvas

2007
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
    American heart journal, 2007, Volume: 153, Issue:4

    Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Enox

2007
Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome.
    International journal of dermatology, 2007, Volume: 46, Issue:4

    Topics: Adult; Anticoagulants; Diagnosis, Differential; Enoxaparin; Female; Humans; Injections, Subcutaneous

2007
Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma.
    The New England journal of medicine, 2007, Jul-05, Volume: 357, Issue:1

    Topics: Adult; Anticoagulants; Constriction, Pathologic; Contraceptives, Oral; Edema; Enoxaparin; Female; Fi

2007
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes.
    The American journal of cardiology, 2007, Sep-15, Volume: 100, Issue:6

    Topics: Administration, Cutaneous; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Comorbidity; C

2007
Guidelines for the management of acute coronary syndromes 2006.
    The Medical journal of Australia, 2007, Sep-17, Volume: 187, Issue:6

    Topics: Aged; Australia; Coronary Disease; Enoxaparin; Humans; Practice Guidelines as Topic; Syndrome

2007
Enoxaparin (Clexane) HITS.
    Anaesthesia and intensive care, 1996, Volume: 24, Issue:5

    Topics: Antibodies; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggr

1996
Enoxaparin (Clexane) HITS.
    Anaesthesia and intensive care, 1996, Volume: 24, Issue:2

    Topics: Anticoagulants; Blood Loss, Surgical; Enoxaparin; Female; Humans; Knee Prosthesis; Middle Aged; Post

1996
Improving outcome in acute coronary syndromes - as good as it gets?
    European heart journal, 1999, Volume: 20, Issue:21

    Topics: Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Platelet Gl

1999
[The treatment of acute coronary syndromes of the "non-ST elevation" type with enoxaparin: the TIMI 11B study. Thrombolysis in Myocardial Infarct].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2000, Volume: 1, Issue:4

    Topics: Acute Disease; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic

2000
Enoxaparin for acute coronary syndromes?
    Journal of the American College of Cardiology, 2001, Jun-01, Volume: 37, Issue:7

    Topics: Acute Disease; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Ischemia; Syndrome

2001
Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes.
    Pharmacotherapy, 2002, Volume: 22, Issue:4

    Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome

2002
Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.
    The American journal of cardiology, 2002, May-15, Volume: 89, Issue:10

    Topics: Acute Disease; Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease

2002
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
    American heart journal, 2002, Volume: 143, Issue:5

    Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar

2002
The primacy of clinical effectiveness for cost effectiveness analysis.
    Heart (British Cardiac Society), 2003, Volume: 89, Issue:3

    Topics: Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dalteparin; Fibrinolytic Agents;

2003
Dalteparin: only protective in hepatic ischemia-reperfusion or also capable of preventing injury in liver hyperperfusion syndrome?
    Critical care medicine, 2006, Volume: 34, Issue:7

    Topics: Animals; Anticoagulants; Dalteparin; Fibrinolytic Agents; Liver; Liver Diseases; Rats; Reperfusion I

2006
New trials of LMW heparins - light and heavy weight as good on short but what about longer distances?
    European heart journal, 1999, Volume: 20, Issue:21

    Topics: Angina, Unstable; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infa

1999
Acute coronary syndromes: extending medical intervention for five days before proceeding to revascularization.
    The American journal of cardiology, 2000, Dec-28, Volume: 86, Issue:12B

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Art

2000
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
    International angiology : a journal of the International Union of Angiology, 2006, Volume: 25, Issue:1

    Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen

2006